Diagonal Bio AB ("Diagonal Bio" or "the Company"), with its point-of-care analysis system LAMPlify®, has received a confirmation from the Japanese Patent Office that the Company’s patent application regarding “A method of measuring the ph of a sample” (no.: JP7655939) has been granted in Japan. The method enables detection with high specificity and selectivity of genetic markers, on par with PCR. The patent is valid until 2041.
At this stage, this patent protection has been extended to Europe, Hong Kong, Israel, Canada, Mexico, South Africa, the UK and Japan. The application is in process in additional countries such as the US, China and Australia.
"We are pleased to announce that our patent has now been granted in Japan. This is an important part of our strategy to strengthen our intellectual property portfolio in global markets. Japan is a highly advanced and competitive region, and this patent approval enhances our ability to protect and commercialize our technology in Asia", says Karin Wehlin, CEO at Diagonal Bio AB.
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.